WEREWOLF THERAPEUTICS, INC.
1030 Massachusetts Avenue, Suite 210
Cambridge, MA 02138
May 18, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Werewolf Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-264844
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Werewolf Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-264844), so that it may become effective at 4:30 p.m. Eastern time on May 20, 2022, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours, |
| WEREWOLF THERAPEUTICS, INC. |
By: /s/ Daniel J. Hicklin |
Name: Daniel J. Hicklin, Ph.D. |
Title: President and Chief Executive Officer |
| cc: | Rosemary G. Reilly |
Stephanie Leopold
Wilmer Cutler Pickering Hale and Dorr LLP
